EDSA
Edesa Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$4.73
−0.63%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- -27.1%
- Free cash flow
- -35.3%
- Operating cash flow
- -35.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +65.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -15.3%
- EBIT
- -12.8%
- Net income
- -16.5%
- EPS
- +34.2%
- Free cash flow
- -49.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026